LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock. The award covers 10,000 shares with an exercise price of $27.95 per share and expires on June 2, 2036.
These options were granted as compensation and not purchased on the open market. All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, if she remains in continuous service through that date. Following this grant, she holds 10,000 stock options directly.
Positive
- None.
Negative
- None.
Insights
Routine director option grant, no open‑market buying or selling.
The filing shows director Rekha Hemrajani receiving 10,000 stock options with a $27.95 exercise price, expiring on June 2, 2036. This is a compensation-related award, not a market transaction, and therefore carries limited signaling value for near-term stock sentiment.
The options vest 100% on the earlier of June 3, 2027 or the next annual stockholder meeting, contingent on continued service. Because there are no sales or open-market purchases and only a single grant, the economic impact is routine and best viewed as standard director equity compensation.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hemrajani Rekha
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 10,000 options
Exercise price: $27.95 per share
Underlying shares: 10,000 shares
+3 more
6 metrics
Stock options granted
10,000 options
Grant to director Rekha Hemrajani
Exercise price
$27.95 per share
Stock option strike price
Underlying shares
10,000 shares
Common stock tied to options
Expiration date
June 2, 2036
Option term end
Post-transaction derivative holdings
10,000 options
Total options held after grant
Vest by date
June 3, 2027 or next annual meeting
100% vesting trigger, continuous service required
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "27.9500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"100% of the shares underlying the option vest on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
FAQ
What did Rekha Hemrajani receive in this LB PHARMACEUTICALS (LBRX) Form 4 filing?
Rekha Hemrajani received a grant of stock options for 10,000 shares of LB PHARMACEUTICALS common stock. The award is a compensation-related grant, not an open-market purchase, and gives her the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the new LBRX stock options granted to Rekha Hemrajani?
The new stock options have an exercise price of $27.95 per share. This means Hemrajani can buy up to 10,000 LB PHARMACEUTICALS shares at $27.95, regardless of future market price, once the options have vested and before they expire.
When do Rekha Hemrajani’s LBRX stock options vest according to the Form 4?
All 10,000 options vest on the earlier of June 3, 2027 or the date of LB PHARMACEUTICALS’ next annual meeting of stockholders. Vesting is conditional on Hemrajani’s continuous service with the company through that vesting date, aligning incentives with ongoing board involvement.
When do the newly granted LBRX stock options to Rekha Hemrajani expire?
The stock options granted to Hemrajani expire on June 2, 2036. She must wait for the options to vest, then exercise them before this expiration date; otherwise, the right to purchase the 10,000 underlying shares at $27.95 per share will lapse.
Does this LBRX Form 4 show any open-market buying or selling by Rekha Hemrajani?
No, the Form 4 only reports a grant of 10,000 stock options as compensation. There are no open-market purchases or sales of LB PHARMACEUTICALS common stock in this filing, so it primarily reflects a standard equity incentive award rather than trading activity.
How many LBRX derivative securities does Rekha Hemrajani hold after this stock option grant?
After the transaction, Hemrajani holds 10,000 stock options linked to LB PHARMACEUTICALS common stock. These options represent the right to acquire 10,000 shares at $27.95 per share once vested, giving her potential future equity exposure if she chooses to exercise them.